SCHEMBL4921272

SCHEMBL4921272

O=C(NO)c1ccccc1-c1ccccc1C(=O)Nc1cccnc1[N+](=O)[O-]

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 3/20 0.46
LMNA P02545 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
HTT P42858 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
TDP1 Q9NUW8 1/20 0.44
KCNMA1 Q12791 1/20 0.44
POLB P06746 2/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
KDR P35968 2/20 0.41
SNCA P37840 1/20 0.41
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916892 0.94 KMT2A (0.49) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL4916917 0.85 KDR (0.47) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL9637625 0.76 NPC1 (0.56) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL28898320 0.75 KMT2A (0.47) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL10745616 0.74 KMT2A (0.53) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL4930503 0.74 SHMT2 (0.48) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL4921271 0.72 KCNMA1 (0.74) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL4927648 0.72 GAA (0.69) KMT2AMEN1LMNASMN1; SMN2HTT
SCHEMBL10477071 0.72 ALDH1A1 (0.57) KMT2AL3MBTL1MEN1LMNASMN1; SMN2
SCHEMBL4923542 0.71 TP53 (0.56) KMT2ALMNASMN1; SMN2HTTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 KMT2A 3374/4885L3MBTL1 2228/4885MEN1 1562/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 KMT2A 3243/4885L3MBTL1 2083/4885MEN1 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.